Nuvation Bio Presents IBTROZI Launch Update, Reports $27.5 Million in Q3 U.S. Net Product Revenue

Bitget2026/11/04 23:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nuvation Bio expects its approximately $663 million cash balance to fund a path to profitability without additional financing.
IBTROZI U.S. net product revenue reached $27.5 million in the third quarter of 2026, up from $23.2 million in the second quarter.
New first-line patient starts captured more than 60% market share as of September 30, 2026; total starts since launch reached approximately 920.
Safusidenib’s pivotal SIGMA study is enrolling patients with high-risk astrocytoma; a phase 3 study in grade 2 glioma is being initiated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nuvation Bio Presents IBTROZI Launch Update, Reports $27.5 Million in Q3 U.S. Net Product Revenue

You may also like

Crypto prices